Hansa Biopharma AB financials
Hansa Biopharma AB
549300LLEO25ZJJ3NT91 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 171.3M | SEK 134.1M |
| Cost of sales | SEK 83.6M | SEK 63.1M |
| Operating profit (EBIT) | -SEK 637.9M | -SEK 788.5M |
| Finance costs | SEK 187.2M | SEK 105.5M |
| Profit before tax | -SEK 804.2M | -SEK 830.8M |
| Income tax expense | SEK 3.0M | SEK 908.0K |
| Profit for the year | -SEK 807.2M | -SEK 831.7M |
| — attributable to owners | -SEK 807.2M | -SEK 831.7M |
| Total comprehensive income | -SEK 805.9M | -SEK 832.1M |
| Per share | ||
| Basic EPS | SEK -12.85 | SEK -15.83 |
| Diluted EPS | SEK -12.85 | SEK -15.83 |
| Free cash flow / share | SEK -10.74 | SEK -14.39 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 674.9M | -SEK 755.7M |
| Net cash from investing activities | -SEK 116.0K | -SEK 284.0K |
| Purchase of PP&E (capex) | SEK 116.0K | SEK 284.0K |
| Net cash from financing activities | SEK 346.8M | -SEK 7.5M |
| Lease liability payments | SEK 7.5M | SEK 7.5M |
| Balance sheet | ||
| Total assets | SEK 800.6M | SEK 1.02B |
| Non-current assets | SEK 215.2M | SEK 162.9M |
| Property, plant & equipment | SEK 4.7M | SEK 6.3M |
| Right-of-use assets | SEK 13.2M | SEK 20.7M |
| Intangible assets & goodwill | SEK 197.3M | SEK 135.8M |
| Current assets | SEK 585.4M | SEK 855.2M |
| Inventories | SEK 2.6M | SEK 1.5M |
| Trade & other receivables | SEK 145.0M | SEK 78.0M |
| Cash & equivalents | SEK 405.3M | SEK 732.1M |
| — attributable to owners | -SEK 589.8M | -SEK 167.9M |
| Non-current liabilities | SEK 1.13B | SEK 864.9M |
| Long-term borrowings | SEK 1.06B | SEK 844.9M |
| Lease liabilities (non-current) | SEK 6.7M | SEK 14.4M |
| Current liabilities | SEK 255.7M | SEK 321.0M |
| Lease liabilities (current) | SEK 7.7M | SEK 7.5M |
| Trade & other payables | SEK 37.6M | SEK 87.0M |
| Deferred tax liabilities | SEK 168.0K | SEK 367.0K |
| Derived metrics | ||
| Free cash flow | -SEK 675.0M | -SEK 755.9M |
| Operating margin | -372.3% | -588.0% |
| Net margin | -471.2% | -620.3% |
| Return on equity | 136.9% | 495.4% |
| Cash conversion ratio | 0.84× | 0.91× |
| Capex coverage | -5817.97× | -2660.75× |
| Other reported items | ||
| Accruals Classified As Current | SEK 109.0M | SEK 112.4M |
| Adjusted Weighted Average Shares | 62.8M | 52.5M |
| Adjustments For Decrease Increase In Other Operating Receivables | SEK 10.0M | SEK 20.6M |
| Adjustments For Decrease Increase In Trade Account Receivable | -SEK 66.9M | -SEK 35.1M |
| Adjustments For Depreciation and Amortisation Expense | SEK 28.1M | SEK 19.8M |
| Adjustments For Increase Decrease In Other Operating Payables | SEK 42.2M | SEK 1.5M |
| Adjustments For Increase Decrease In Trade Account Payable | -SEK 49.3M | SEK 24.5M |
| Adjustments For Sharebased Payments | SEK 31.7M | SEK 60.6M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | SEK 187.8M | SEK 44.6M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 626.4M | -SEK 793.9M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 805.9M | -SEK 832.1M |
| Current Deferred Income Other Than Current Contract Liabilities | SEK 16.3M | SEK 41.5M |
| Current Prepayments and Current Accrued Income Other Than Current Contract Assets | SEK 17.5M | SEK 21.5M |
| Current Tax Liabilities Current | SEK 2.7M | SEK 1.6M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 1.4M | -SEK 636.0K |
| Equity and Liabilities | SEK 800.6M | SEK 1.02B |
| Finance Income | SEK 20.8M | SEK 63.2M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 3.6M | SEK 133.0K |
| Increase Decrease In Cash and Cash Equivalents | -SEK 328.2M | -SEK 763.5M |
| Increase Decrease In Working Capital | SEK 64.0M | -SEK 11.4M |
| Interest Received Classified As Operating Activities | SEK 19.1M | SEK 27.0M |
| Issued Capital | SEK 67.8M | SEK 55.0M |
| Noncurrent Provisions | SEK 4.3M | SEK 4.5M |
| Other Adjustments For Noncash Items | -SEK 66.6M | -SEK 87.2M |
| Other Comprehensive Income | SEK 1.4M | -SEK 422.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 1.4M | -SEK 422.0K |
| Other Current Liabilities | SEK 17.9M | SEK 21.8M |
| Other Current Payables | SEK 64.5M | SEK 49.3M |
| Other Current Receivables | SEK 15.1M | SEK 22.0M |
| Other Noncurrent Liabilities | SEK 0 | SEK 843.0K |
| Other Operating Income Expense | -SEK 5.7M | SEK 2.4M |
| Other Reserves | SEK 942.0K | -SEK 408.0K |
| Proceeds From Issuing Shares | SEK 354.3M | SEK 0 |
| Research and Development Expense | SEK 375.7M | SEK 411.3M |
| Retained Earnings | -SEK 4.11B | -SEK 3.30B |
| Selling General and Administrative Expense | SEK 344.3M | SEK 450.5M |
| Share Issue Related Cost | SEK 17.8M | — |
| Share Premium | SEK 3.45B | SEK 3.08B |
| Treasury Shares | SEK 0 | SEK 2.4M |
| Weighted Average Shares | 62.8M | 52.5M |
Every line item above is a fact tagged in Hansa Biopharma AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.